Sagility Q2 Results: Net profit up 13% on 23% revenue growth; declares dividend

Healthcare technology services provider Sagility Ltdon Thursday reported a 13.1% year-on-year increase in net profit to ₹284 crore for the quarter ended September 30, 2026, compared with ₹251 crore in the year-ago period.Revenue grew 22.6% to ₹2,032 crore from ₹1,658 crore, while earnings before interest, tax, depreciation and amortisation rose 23.4% to ₹512 crore from ₹415 crore. The EBITDA margin remained flat at 25% year-on-year.The company's organic revenue growth stood at 22.2% during the quarter, or 11.9% in constant currency terms. Adjusted EBITDA increased 23% year-on-year to ₹535.3 crore , accounting for 26.3% of revenue.ALSO READ | Sagility Q4 net profit climbs 41%, revenue up 29%; declares dividendAdjusted profit after tax rose 8.1% to ₹325.4 crore , representing 16% of revenue.

Basic earnings per share increased 13.3% year-on-year to ₹0.61, while adjusted basic EPS rose 8.1% to ₹0.70.The board of directors declared an interim dividend of ₹0.15 per equity share of face value ₹10 for the financial year 2026–27. The record date is October 30, 2026, and the dividend will be paid on or before November 21, 2026.Sagility H1 FY27For the half year ended September 30, 2026, revenue increased 25% year-on-year to ₹3,995.6 crore , compared with ₹3,196.48 crore in the year-ago period, based on the reported growth rate. Organic revenue growth stood at 24.7%, or 13.4% in constant currency terms.ALSO READ | Sagility Q3 net jumps 23% to ₹268 cr as revenue soars 36%, margins steadyAdjusted EBITDA rose 25.2% year-on-year to ₹1,006.9 crore , accounting for 25.2% of revenue.

Adjusted PAT increased 18.9% to ₹595.1 crore , representing 14.9% of revenue. Basic EPS rose 25.4% year-on-year to ₹1.07, while adjusted basic EPS increased 18.9% to ₹1.27.Ramesh Gopalan, Managing Director and Group CEO, said, "Our performance in the first half of FY27 reflects broad-based momentum across the business. Our pipeline is healthy with larger deals and a growing set of opportunities with Blues and mid-market plans.Our AI solutions are gaining traction, with new SOW wins and more solutions moving into production.

CareSeed is now integrated into our Clinical Practice, adding depth to our healthcare quality capabilities, and our recent acquisition of Chirok will accelerate our growth in the provider segment, strengthening our end-to-end provider RCM capabilities.ALSO READ | Sagility India's Q1 profit jumps 46% as revenue grows, client base expandsAs we enter the second half, our priority is disciplined execution through the AEP and Open Enrollment season, while investing in the capabilities that will drive our next phase of growth."Sagility secured $40.2 million in annual contract value from 31 existing clients and one new client during Q2 FY27.The company added 28 client groups in the first half of FY27, including clients acquired through the CareSeed acquisition, taking its total active client group base to 105.At the end of Q2 FY27, Sagility had 51,486 employees. As of September 30, 2026, the company had a presence in five countries, with 28 delivery centres.ALSO READ | Sagility sees low double-digit revenue growth in FY27 as AI-led healthcare deals pick upSrinivas Mattapalli, Group Chief Financial Officer, added, "Q2 FY27 was a strong quarter with healthy growth, robust cash generation and our highest adjusted EBITDA margin in six quarters, reflecting disciplined execution, operating leverage and delivery efficiencies. Our revenue trajectory demonstrates the resilience of the operating model as we enter the seasonally stronger H2.Underscoring our confidence in the business and our commitment to shareholder returns, the Board has declared an interim dividend of ₹0.15 per share, up from ₹0.05 in the previous interim. We will continue to invest selectively in technology, AI and domain-led growth to create long-term value for our stakeholders."Shares of Sagility Ltd ended at ₹45.45, up by ₹1.13, or 2.55%, on the BSE.